GLP-3RT – 50mg

$215

Escrow: Auto-Finalized in 13 Days
Shipping from: 🇪🇺 European Union or 🇺🇸 United States
Shipping to: 🌍 Worldwide


Support email: shadowgatemarket@proton.me
SOLD: 379

32220 in stock

Item will be shipped in 1 business day
0 out of 5
Category:

This item is listed as an Escrow Product. The order process is as follows

After ordering, all payments will be held by the Market(Admin) for up to 14 days. If the customer does not receive the product within this period, a full refund will be issued to the customers account. We only release payments to vendors/sellers after the customer confirms they have received their product. This escrow system ensures zero scams on the market. Happy shopping on ShadowGate Market, with zero tolerance for scams.

Description

Triple agonist peptide (GIP/GLP-1/Glucagon) – formerly Reta/Retatrutide

Purity

99%+

Retatrutide is a cutting-edge triple agonist peptide that simultaneously
activates glucose-dependent insulinotropic polypeptide (GIP),
glucagon-like peptide-1 (GLP-1), and glucagon receptors. This represents
the next generation in multi-receptor peptide research, offering
scientists an unprecedented tool for studying complex metabolic
interactions. Research applications focus on understanding how triple
receptor activation influences energy expenditure, insulin sensitivity,
glucagon regulation, appetite control, and fat oxidation. Scientists
investigate the synergistic and potentially additive effects of
targeting three distinct but interconnected metabolic pathways. Studies
examine its impact on glucose homeostasis, body composition, energy
balance, hepatic metabolism, and thermogenesis. The compound provides
unique insights into the coordination between different hormonal systems
and their combined influence on metabolic outcomes. Valuable for
advanced metabolic research and understanding integrated hormonal
regulation.



Reviews

There are no reviews yet.

Be the first to review “GLP-3RT – 50mg”
No more offers for this product!

General Inquiries

There are no inquiries yet.